1. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event

   • Peng Huang
   • William Plunkett

   Original Article Pages: 181 - 188

2. Phase I study of NKT-01

   • Kazuo Tamura
   • Hisanobu Niitani
   • Kiyoji Kimura

   Original Article Pages: 189 - 194

3. In vitro activity of S 9788 on a multidrug-resistant leukemic cell line and on normal hematopoietic cells—reversal of multidrug resistance by sera from phase I-treated patients

   • Jacques Soudon
   • Maryse Berlion
   • Fabien Calvo

   Original Article Pages: 195 - 203

4. Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies

   • Richard A. Larson
   • Robert B. Geller
   • Mark J. Ratain

   Original Article Pages: 204 - 210

5. Safety and efficacy of intraperitoneal injection of etoposide in oil suspension in mice with peritoneal carcinomatosis

   • Jung Soo Lee
   • Toshio Takahashi
   • Shigeru Tashima

   Original Article Pages: 211 - 216

6. Antitumor activity of FCE 26644 a new growth-factor complexing molecule

   • Francesco Sola
   • Mariella Farao
   • Maria Grandi

   Original Article Pages: 217 - 222

7. Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metabolites in human MDR1 transfected NIH-3T3 cells

   • Mary J. Kuffel
   • Matthew M. Ames

   Original Article Pages: 223 - 226

8. Pretreatment H₂ receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia

   • William J. Slichemyer
   • Ross C. Donehower
   • Eric K. Rowinsky

   Original Article Pages: 227 - 232

9. A limited sampling strategy for the study of pirarubicin pharmacokinetics in humans

   • Dominique Marchiset-Leca
   • François-René Leca
   • Athanassios Iliadis

   Original Article Pages: 233 - 238

10. Pharmacokinetics and metabolism of pirarubicin in humans: correlation with pharmacodynamics

    • Dominique Marchiset-Leca
    • Francois-René Leca
    • Jacques Catalin

    Original Article Pages: 239 - 243

11. Experimental solid tumour activity ofN-[2-(dimethylamino)ethyl]-acridine-4-carboxamide

    • Bruce C. Baguley
    • Li Zhuang
    • Elaine Marshall

    Original Article Pages: 244 - 248

12. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients

    • F. A. MacNeill
    • S. Jacobs
    • T. J. Powles

    Original Article Pages: 249 - 254

13. Treatment of advanced gastric cancer with the combination fluorouracil, leucovorin, etoposide, and cisplatin: a phase II study of the ONCOPAZ cooperative group

    • M. González-Barón
    • J. Feliu
    • P. Zamora

    Clinical Trial Report Pages: 255 - 258

14. Phase I–II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer

    • C. Maulard
    • P. Richaud
    • M. Housset

    Clinical Trial Report Pages: 259 - 262

15. Oral trofosfamide: an active drug in the treatment of soft-tissue sarcoma

    • Carl Blomqvist
    • Tom Wiklund
    • Inkeri Elomaa

    Clinical Trial Report Pages: 263 - 265

16. Development and validation of a sensitive solid-phase-extraction and high-performance liquid chromatography assay for the bioreductive agent tirapazamine and its major metabolites in mouse and human plasma for pharmacokinetically guided dose escalation

    • Hernani Robin Jr.
    • Suresh Senan
    • Martin A. Graham

    Short Communication Pages: 266 - 270

17. Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia

    • William J. Slichenmyer
    • Ross C. Donehower
    • Tian-Lingchen

    ORIGINAL ARTICLE Pages: 227 - 232

18. Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer

    • C. Maulard
    • P. Richaud
    • F. Dufour-Esguerré

    CLINICAL TRIAL REPORT Pages: 259 - 262